|
|
|
| Join Cencora this May 14-15 for our inaugural ThinkLive Cell and Gene Therapy Virtual Summit. This event will bring together global and emerging company leaders, providers, and experts who are shaping the future of healthcare. With over 30 speakers, 10 live sessions, and 6 focus areas, this event will provide valuable insights into the latest trends and strategies driving commercial success in CGT. View the agenda and register today. |
|
|
|
|
By Alex Santos, CMC regulatory scientist | By integrating rather than transferring technology, partnerships with CDMOs have the potential to streamline development, focus on characterization, and strengthen dossiers for regulatory submissions. |
|
|
|
Why understanding composition and what may or may not interfere in your culture process is key to operations in reducing variability. |
|
|
|
|
| A CDMO’s Checklist For Prospective Clients: Part 3 | Article | Theragent | In the last entry of our client checklist series, we delve into crucial aspects such as project management, decision-making, MSA negotiations, and building trust in CDMO-client partnerships. |
|
|
|
|
|
| XOFLX Lenti Platform: Comparable To The Four-Plasmid Process | Poster | By M. Tridgett, M. Mulet, et al., WuXi Advanced Therapies | Examine how this innovative platform has the potential to unlock the full potential of cell and gene therapy, bringing these life-changing treatments to a wider range of patients. |
|
|
|
|
|
| Breaking down the latest in allogeneic therapy research as well as immunogenicity and the strategies needed to deliver clinically successful and long-lasting off-the-shelf treatments to patients in oncology. Don’t miss the next Cell & Gene Live. Supported by Thermo Fisher Scientific. Register now |
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
